Related Experiment Video

Updated: Jun 14, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

CIAPIN1 as a therapeutic target in cancer

Xiaohua Li1, Kaichun Wu, Daiming Fan

  • 1The Fourth Military Medical University, State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases, 17 Changle Western Road, Xi'an, 710032, China.

Expert Opinion on Therapeutic Targets
|April 7, 2010
PubMed
Abstract

Insights

Cytokine-induced apoptosis inhibitor 1 (CIAPIN1) shows promise as a cancer target. Targeting CIAPIN1 may overcome chemotherapy resistance and improve patient survival, though its precise role requires further study.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cytokine-induced apoptosis inhibitor 1 (CIAPIN1) is implicated in cell division and angiogenesis.
  • CIAPIN1's prognostic value in human tumors and role in cancer progression and drug resistance make it a potential therapeutic target.

Purpose of the Study:

  • To review the literature on CIAPIN1's role in cancer over the past five years.
  • To define CIAPIN1's potential as a therapeutic target for anticancer interventions.

Main Methods:

  • Comprehensive literature review of studies on CIAPIN1 in cancer.
  • Analysis of preclinical data on CIAPIN1's association with cancer hallmarks.

Main Results:

  • Preclinical studies link CIAPIN1 to chemotherapy resistance, tumor recurrence, and reduced patient survival.
  • CIAPIN1 overexpression may inhibit proliferation and tumorigenesis in some malignant tumors.
  • Low CIAPIN1 expression is observed in certain cancer types.

Conclusions:

  • Further research is needed to fully characterize CIAPIN1 expression and function in normal versus tumor tissues.
  • Understanding CIAPIN1's differential roles is crucial for developing targeted cancer therapies.
  • Selective disruption of CIAPIN1 in cancer presents a promising therapeutic strategy.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...